Autologous hematopoietic stem cell transplantation (aHSCT) is a well-established treatment
for malignancies such as multiple myeloma (MM) and lymphomas. Various changes in the …

Plerixafor was recently approved by the US Food and Drug Administration (FDA) and the
European Medicines Evaluation Agency (EMEA) to enhance stem cell mobilization for …

Autologous hematopoietic stem cell (HSC) transplant is an effective treatment for patients
with hematological malignancies. Unfortunately, 15–30% of patients fail to mobilize a …

Plerixafor, a novel CXCR4 inhibitor, is effective in mobilizing PBSCs particularly when used
in conjunction with G-CSF. In four cohorts, this pilot study explored the safety of plerixafor …

Plerixafor (Mozobil®) is a CXCR4 chemokine receptor antagonist that is indicated for use in
combination with granulocyte colony-stimulating factor (G-CSF) to mobilize stem cells to the …

Abstract This phase 3, multicenter, randomized (1: 1), double-blind, placebo-controlled study
evaluated the safety and efficacy of plerixafor with granulocyte colony-stimulating factor (G …

This was an open-label, single-center, phase II study of 20 patients with multiple myeloma
who were either proven poor mobilizers (n= 10; group A) or predicted poor mobilizers (n …

Preapheresis peripheral blood (PB) CD34+ cell count is a strong predictor of hematopoietic
stem cell (HSC) mobilization and is routinely used to optimize the timing, cost, and success …

Collection of adequate hematopoietic stem cells (HSCs) is necessary for successful
autologous transplantation; however, a proportion of patients fail to collect the minimum …

Abstract Transplantation with 2-5× 106 mobilized CD34+ cells/kg body weight lowers
transplantation costs and mortality. Mobilization is most commonly performed with …